Low FODMAP Diet and Probiotics in Irritable Bowel Syndrome: A Systematic Review With Network Meta-analysis

Background: Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients with irritable bowel syndrome (IBS). We aimed to evaluate the most effective combinations and components among different probioti...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 13; p. 853011
Main Authors Xie, Chao-Rong, Tang, Bin, Shi, Yun-Zhou, Peng, Wen-Yan, Ye, Kun, Tao, Qing-Feng, Yu, Shu-Guang, Zheng, Hui, Chen, Min
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 09.03.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background: Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients with irritable bowel syndrome (IBS). We aimed to evaluate the most effective combinations and components among different probiotics or low FODMAP diet through component network meta-analysis (NMA). Methods: We searched Embase, Ovid Medline, and Web of Science from inception to 21 January 2021. Randomized controlled trials (RCTs) examining the efficacy of probiotics and low FODMAP diet for IBS were included, with placebo, sham diet, or conventional treatments as controls. Binary outcomes were compared among treatments using the relative ratio (RR). A minimally contextualized framework recommended by the GRADE group was used to evaluate the certainty of evidence. The primary efficacy outcome was the relief of global IBS symptoms, and the secondary efficacy outcome was the reduction in IBS symptom scores or abdominal pain scores. Key Results: We included 76 RCTs (n = 8058) after screening 1940 articles. Eight RCTs were classified as low risk of bias. Standard network meta-analysis (NMA) showed that Lactobacillus (RR 1.74, 95% CI 1.22–2.48) and Bifidobacterium (RR 1.76, 95% CI 1.01–3.07) were the most effective for the primary efficacy outcome (high certainty evidence); component NMA showed that Bacillus (RR 5.67, 95% CI 1.88 to 17.08, p = 0.002) and Lactobacillus (RR 1.42, 95% CI 1.07 to 1.91, p = 0.017) were among the most effective components. The results of standard NMA and CNMA analysis of the improvement of overall IBS symptom scores or abdominal pain scores were consistent with this finding. Conclusion: Lactobacillus was the most effective component for the relief of IBS symptoms; Bifidobacterium and Bacillus were possibly effective and need further verification. Systematic Review Registration: website, identifier registration number.
AbstractList Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients with irritable bowel syndrome (IBS). We aimed to evaluate the most effective combinations and components among different probiotics or low FODMAP diet through component network meta-analysis (NMA). We searched Embase, Ovid Medline, and Web of Science from inception to 21 January 2021. Randomized controlled trials (RCTs) examining the efficacy of probiotics and low FODMAP diet for IBS were included, with placebo, sham diet, or conventional treatments as controls. Binary outcomes were compared among treatments using the relative ratio (RR). A minimally contextualized framework recommended by the GRADE group was used to evaluate the certainty of evidence. The primary efficacy outcome was the relief of global IBS symptoms, and the secondary efficacy outcome was the reduction in IBS symptom scores or abdominal pain scores. We included 76 RCTs (n = 8058) after screening 1940 articles. Eight RCTs were classified as low risk of bias. Standard network meta-analysis (NMA) showed that (RR 1.74, 95% CI 1.22-2.48) and (RR 1.76, 95% CI 1.01-3.07) were the most effective for the primary efficacy outcome (high certainty evidence); component NMA showed that (RR 5.67, 95% CI 1.88 to 17.08, = 0.002) and (RR 1.42, 95% CI 1.07 to 1.91, = 0.017) were among the most effective components. The results of standard NMA and CNMA analysis of the improvement of overall IBS symptom scores or abdominal pain scores were consistent with this finding. was the most effective component for the relief of IBS symptoms; and were possibly effective and need further verification. website, identifier registration number.
Background: Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients with irritable bowel syndrome (IBS). We aimed to evaluate the most effective combinations and components among different probiotics or low FODMAP diet through component network meta-analysis (NMA).Methods: We searched Embase, Ovid Medline, and Web of Science from inception to 21 January 2021. Randomized controlled trials (RCTs) examining the efficacy of probiotics and low FODMAP diet for IBS were included, with placebo, sham diet, or conventional treatments as controls. Binary outcomes were compared among treatments using the relative ratio (RR). A minimally contextualized framework recommended by the GRADE group was used to evaluate the certainty of evidence. The primary efficacy outcome was the relief of global IBS symptoms, and the secondary efficacy outcome was the reduction in IBS symptom scores or abdominal pain scores.Key Results: We included 76 RCTs (n = 8058) after screening 1940 articles. Eight RCTs were classified as low risk of bias. Standard network meta-analysis (NMA) showed that Lactobacillus (RR 1.74, 95% CI 1.22–2.48) and Bifidobacterium (RR 1.76, 95% CI 1.01–3.07) were the most effective for the primary efficacy outcome (high certainty evidence); component NMA showed that Bacillus (RR 5.67, 95% CI 1.88 to 17.08, p = 0.002) and Lactobacillus (RR 1.42, 95% CI 1.07 to 1.91, p = 0.017) were among the most effective components. The results of standard NMA and CNMA analysis of the improvement of overall IBS symptom scores or abdominal pain scores were consistent with this finding.Conclusion:Lactobacillus was the most effective component for the relief of IBS symptoms; Bifidobacterium and Bacillus were possibly effective and need further verification.Systematic Review Registration: website, identifier registration number.
Background: Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients with irritable bowel syndrome (IBS). We aimed to evaluate the most effective combinations and components among different probiotics or low FODMAP diet through component network meta-analysis (NMA). Methods: We searched Embase, Ovid Medline, and Web of Science from inception to 21 January 2021. Randomized controlled trials (RCTs) examining the efficacy of probiotics and low FODMAP diet for IBS were included, with placebo, sham diet, or conventional treatments as controls. Binary outcomes were compared among treatments using the relative ratio (RR). A minimally contextualized framework recommended by the GRADE group was used to evaluate the certainty of evidence. The primary efficacy outcome was the relief of global IBS symptoms, and the secondary efficacy outcome was the reduction in IBS symptom scores or abdominal pain scores. Key Results: We included 76 RCTs (n = 8058) after screening 1940 articles. Eight RCTs were classified as low risk of bias. Standard network meta-analysis (NMA) showed that Lactobacillus (RR 1.74, 95% CI 1.22–2.48) and Bifidobacterium (RR 1.76, 95% CI 1.01–3.07) were the most effective for the primary efficacy outcome (high certainty evidence); component NMA showed that Bacillus (RR 5.67, 95% CI 1.88 to 17.08, p = 0.002) and Lactobacillus (RR 1.42, 95% CI 1.07 to 1.91, p = 0.017) were among the most effective components. The results of standard NMA and CNMA analysis of the improvement of overall IBS symptom scores or abdominal pain scores were consistent with this finding. Conclusion: Lactobacillus was the most effective component for the relief of IBS symptoms; Bifidobacterium and Bacillus were possibly effective and need further verification. Systematic Review Registration: website, identifier registration number.
Background: Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients with irritable bowel syndrome (IBS). We aimed to evaluate the most effective combinations and components among different probiotics or low FODMAP diet through component network meta-analysis (NMA). Methods: We searched Embase, Ovid Medline, and Web of Science from inception to 21 January 2021. Randomized controlled trials (RCTs) examining the efficacy of probiotics and low FODMAP diet for IBS were included, with placebo, sham diet, or conventional treatments as controls. Binary outcomes were compared among treatments using the relative ratio (RR). A minimally contextualized framework recommended by the GRADE group was used to evaluate the certainty of evidence. The primary efficacy outcome was the relief of global IBS symptoms, and the secondary efficacy outcome was the reduction in IBS symptom scores or abdominal pain scores. Key Results: We included 76 RCTs (n = 8058) after screening 1940 articles. Eight RCTs were classified as low risk of bias. Standard network meta-analysis (NMA) showed that Lactobacillus (RR 1.74, 95% CI 1.22-2.48) and Bifidobacterium (RR 1.76, 95% CI 1.01-3.07) were the most effective for the primary efficacy outcome (high certainty evidence); component NMA showed that Bacillus (RR 5.67, 95% CI 1.88 to 17.08, p = 0.002) and Lactobacillus (RR 1.42, 95% CI 1.07 to 1.91, p = 0.017) were among the most effective components. The results of standard NMA and CNMA analysis of the improvement of overall IBS symptom scores or abdominal pain scores were consistent with this finding. Conclusion: Lactobacillus was the most effective component for the relief of IBS symptoms; Bifidobacterium and Bacillus were possibly effective and need further verification. Systematic Review Registration: website, identifier registration number.Background: Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients with irritable bowel syndrome (IBS). We aimed to evaluate the most effective combinations and components among different probiotics or low FODMAP diet through component network meta-analysis (NMA). Methods: We searched Embase, Ovid Medline, and Web of Science from inception to 21 January 2021. Randomized controlled trials (RCTs) examining the efficacy of probiotics and low FODMAP diet for IBS were included, with placebo, sham diet, or conventional treatments as controls. Binary outcomes were compared among treatments using the relative ratio (RR). A minimally contextualized framework recommended by the GRADE group was used to evaluate the certainty of evidence. The primary efficacy outcome was the relief of global IBS symptoms, and the secondary efficacy outcome was the reduction in IBS symptom scores or abdominal pain scores. Key Results: We included 76 RCTs (n = 8058) after screening 1940 articles. Eight RCTs were classified as low risk of bias. Standard network meta-analysis (NMA) showed that Lactobacillus (RR 1.74, 95% CI 1.22-2.48) and Bifidobacterium (RR 1.76, 95% CI 1.01-3.07) were the most effective for the primary efficacy outcome (high certainty evidence); component NMA showed that Bacillus (RR 5.67, 95% CI 1.88 to 17.08, p = 0.002) and Lactobacillus (RR 1.42, 95% CI 1.07 to 1.91, p = 0.017) were among the most effective components. The results of standard NMA and CNMA analysis of the improvement of overall IBS symptom scores or abdominal pain scores were consistent with this finding. Conclusion: Lactobacillus was the most effective component for the relief of IBS symptoms; Bifidobacterium and Bacillus were possibly effective and need further verification. Systematic Review Registration: website, identifier registration number.
Author Xie, Chao-Rong
Tao, Qing-Feng
Yu, Shu-Guang
Zheng, Hui
Chen, Min
Peng, Wen-Yan
Shi, Yun-Zhou
Ye, Kun
Tang, Bin
AuthorAffiliation 1 The Third Hospital/Acupuncture and Tuina School , Chengdu University of Traditional Chinese Medicine , Chengdu , China
3 Department of Colorectal Diseases , Hospital of Chengdu University of Traditional Chinese Medicine , Chengdu University of Traditional Chinese Medicine , Chengdu , China
2 Digestive Department , People’s Hospital of Zhongjiang County , Zhongjiang , China
AuthorAffiliation_xml – name: 2 Digestive Department , People’s Hospital of Zhongjiang County , Zhongjiang , China
– name: 3 Department of Colorectal Diseases , Hospital of Chengdu University of Traditional Chinese Medicine , Chengdu University of Traditional Chinese Medicine , Chengdu , China
– name: 1 The Third Hospital/Acupuncture and Tuina School , Chengdu University of Traditional Chinese Medicine , Chengdu , China
Author_xml – sequence: 1
  givenname: Chao-Rong
  surname: Xie
  fullname: Xie, Chao-Rong
– sequence: 2
  givenname: Bin
  surname: Tang
  fullname: Tang, Bin
– sequence: 3
  givenname: Yun-Zhou
  surname: Shi
  fullname: Shi, Yun-Zhou
– sequence: 4
  givenname: Wen-Yan
  surname: Peng
  fullname: Peng, Wen-Yan
– sequence: 5
  givenname: Kun
  surname: Ye
  fullname: Ye, Kun
– sequence: 6
  givenname: Qing-Feng
  surname: Tao
  fullname: Tao, Qing-Feng
– sequence: 7
  givenname: Shu-Guang
  surname: Yu
  fullname: Yu, Shu-Guang
– sequence: 8
  givenname: Hui
  surname: Zheng
  fullname: Zheng, Hui
– sequence: 9
  givenname: Min
  surname: Chen
  fullname: Chen, Min
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35355730$$D View this record in MEDLINE/PubMed
BookMark eNp9kk1vEzEQhleoiJbSH8AF-cglwWuvP5YDUtpSiJTSig9xtMbe2cZhsw620yj_nk1TqpYDvnhkv_O8I837sjjoQ49F8bqkY851_a5dzSGOGWVsrAWnZfmsOCql5KNal-zgUX1YnKS0oMPhdc1l9aI45IILoTg9KhazsCEXV-eXk2ty7jET6BtyHYP1IXuXiO_JNEafwXZITsMGO_Jt2zcxLPE9mQx1yriEQUq-4q3HDfnp85x8wbwJ8Re5xAwj6KHbJp9eFc9b6BKe3N_HxY-Lj9_PPo9mV5-mZ5PZyFVS5BE6lK1SlEEjnWLWYkOpsBIoMLDKVUpJRZVQwKyUSteU1pq1KJoKZOVqflxM99wmwMKsol9C3JoA3tw9hHhjIA4Td2gqqkGWDlxjy0rV1tbQCuCUKQdat9XA-rBnrdZ2iY3DPkfonkCf_vR-bm7CrdG1qIViA-DtPSCG32tM2Sx9cth10GNYJ8NkJbSQpd55vXns9WDyd1mDoNwLXAwpRWwfJCU1u0yYu0yYXSbMPhNDj_qnxw3LzD7sxvXdfzr_AFbgvRQ
CitedBy_id crossref_primary_10_1039_D3FO03717G
crossref_primary_10_3390_ijms241914562
crossref_primary_10_3390_jcm12144838
crossref_primary_10_1007_s12602_023_10151_w
crossref_primary_10_3390_ijms25052550
crossref_primary_10_11569_wcjd_v30_i20_886
crossref_primary_10_3390_nu16071027
crossref_primary_10_3390_nu16111727
crossref_primary_10_1002_iid3_857
crossref_primary_10_1038_s41392_023_01673_4
crossref_primary_10_1097_MOG_0000000000000902
crossref_primary_10_70749_ijbr_v3i3_822
Cites_doi 10.1136/bmj.l4898
10.1007/s10068-019-00717-2
10.1111/j.1365-2036.2011.04633.x
10.1111/j.1365-2036.2008.03853.x
10.3748/wjg.v20.i26.8709
10.1186/1471-230X-13-45
10.3748/wjg.v18.i17.2067
10.1097/MD.0000000000016068
10.3390/nu11122887
10.1155/2013/824605
10.1159/000510950
10.1016/j.nut.2017.07.004
10.1136/bmj.m3900
10.1016/j.ctim.2019.07.001
10.1111/nmo.12320
10.14309/ajg.0000000000000641
10.1053/j.gastro.2016.03.035
10.1007/s10620-007-0196-4
10.1186/s12955-017-0611-2
10.1111/j.1365-2036.2005.02579.x
10.1097/MCG.0b013e31823712b1
10.3109/02813438909103666
10.1007/s00394-020-02473-0
10.1016/j.dld.2014.11.007
10.1053/j.gastro.2016.02.031
10.3109/00365521.2013.825314
10.1111/apt.15001
10.1046/j.1365-2036.1997.142318000.x
10.1046/j.1365-2036.2003.01543.x
10.1155/2012/214102
10.1038/s41395-018-0195-4
10.3389/fphar.2020.00332
10.1053/j.gastro.2020.05.059
10.1053/j.gastro.2017.06.010
10.1016/j.gcb.2007.06.001
10.1038/s41395-018-0262-x
10.1016/j.ijsu.2020.01.142
10.1053/j.gastro.2016.02.010
10.1111/j.1572-0241.2006.00734.x
10.1111/nmo.13037
10.1053/j.gastro.2017.05.003
10.1016/j.dld.2019.12.009
10.3390/nu11091968
10.3390/nu13030756
10.1038/ajg.2014.148
10.3810/pgm.2009.03.1984
10.1038/s41598-019-48554-x
10.1002/bimj.201900339
10.1111/jgh.15410
10.3748/wjg.v22.i48.10631
10.1016/S0140-6736(20)31548-8
10.1111/jgh.12322
10.1186/1751-0759-6-16
10.1111/apt.13286
10.1111/j.1365-2036.2007.03542.x
10.1007/s00384-011-1363-9
10.3390/nu12020363
10.3748/wjg.v18.i30.4012
10.3748/wjg.v20.i43.16215
10.1111/j.1365-2982.2005.00695.x
10.1097/MEG.0000000000000094
10.1007/s10620-014-3299-8
10.1136/gutjnl-2015-311339
10.1007/s12602-010-9059-y
10.1097/00042737-200110000-00004
10.4161/gmic.24196
10.1097/MEG.0000000000000484
10.3390/nu11122856
10.1002/bimj.201800167
10.1007/s00384-019-03462-4
10.3164/jcbn.15-14
10.1136/gutjnl-2021-325214
10.1055/s-2008-1027702
10.1111/j.1365-2036.2008.03848.x
10.5009/gnl.2009.3.2.101
10.3164/jcbn.17-73
10.1111/j.1365-2036.2008.03818.x
10.3945/jn.112.159285
10.1097/MCG.0b013e318204593e
10.14309/ajg.0000000000001036
10.1016/j.clnu.2005.06.001
10.1056/NEJMra1607547
10.1016/S2468-1253(20)30056-X
10.3390/jcm10163497
10.1002/jrsm.1058
10.1038/ajg.2014.202
10.1111/apt.12787
10.1038/ajg.2016.434
10.1053/j.gastro.2020.04.014
10.1053/j.gastro.2015.07.054
10.1016/j.nut.2014.02.010
10.1046/j.1572-0241.2003.04024.x
10.1111/j.1365-2036.2007.03362.x
10.1177/2050640615602571
10.1111/j.1365-2036.2009.04183.x
10.3390/nu12041159
10.1097/MCG.0b013e31820ca4d6
10.3109/00365521.2011.565066
10.1136/gutjnl-2018-318160
10.1111/j.1572-0241.2000.02015.x
10.1097/SGA.0000000000000428
ContentType Journal Article
Copyright Copyright © 2022 Xie, Tang, Shi, Peng, Ye, Tao, Yu, Zheng and Chen.
Copyright © 2022 Xie, Tang, Shi, Peng, Ye, Tao, Yu, Zheng and Chen. 2022 Xie, Tang, Shi, Peng, Ye, Tao, Yu, Zheng and Chen
Copyright_xml – notice: Copyright © 2022 Xie, Tang, Shi, Peng, Ye, Tao, Yu, Zheng and Chen.
– notice: Copyright © 2022 Xie, Tang, Shi, Peng, Ye, Tao, Yu, Zheng and Chen. 2022 Xie, Tang, Shi, Peng, Ye, Tao, Yu, Zheng and Chen
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fphar.2022.853011
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Full Text
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed

CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Xie et al
EISSN 1663-9812
ExternalDocumentID oai_doaj_org_article_408a61cacdb1479bb9af5a3027ca88f4
PMC8959572
35355730
10_3389_fphar_2022_853011
Genre Journal Article
Review
GrantInformation_xml – fundername: ;
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
RNS
RPM
IAO
IEA
IHR
IHW
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c465t-ece6f7702ad6c72bbed005b6a0a2ab7c477670757a2b6678900982fe5d4a64c93
IEDL.DBID M48
ISSN 1663-9812
IngestDate Wed Aug 27 01:03:38 EDT 2025
Thu Aug 21 18:45:40 EDT 2025
Fri Jul 11 13:41:39 EDT 2025
Thu Jan 02 22:55:35 EST 2025
Thu Apr 24 23:04:59 EDT 2025
Tue Jul 01 03:27:56 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords component network meta-analysis
disaccharides
and polyols
irritable bowel syndrome
low fermentable oligosaccharides
monosaccharides
systematic review
probiotics
Language English
License Copyright © 2022 Xie, Tang, Shi, Peng, Ye, Tao, Yu, Zheng and Chen.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c465t-ece6f7702ad6c72bbed005b6a0a2ab7c477670757a2b6678900982fe5d4a64c93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
This article was submitted to Gastrointestinal and Hepatic Pharmacology, a section of the journal Frontiers in Pharmacology
Edited by: Raffaele Capasso, University of Naples Federico II, Italy
These authors have contributed equally to this work
Reviewed by: Chris Probert, University of Liverpool, United Kingdom
Isabelle Mack, University of Tübingen, Germany
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fphar.2022.853011
PMID 35355730
PQID 2645856184
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_408a61cacdb1479bb9af5a3027ca88f4
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8959572
proquest_miscellaneous_2645856184
pubmed_primary_35355730
crossref_primary_10_3389_fphar_2022_853011
crossref_citationtrail_10_3389_fphar_2022_853011
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-03-09
PublicationDateYYYYMMDD 2022-03-09
PublicationDate_xml – month: 03
  year: 2022
  text: 2022-03-09
  day: 09
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in pharmacology
PublicationTitleAlternate Front Pharmacol
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Jafari (B41) 2014; 17
Staudacher (B91) 2012; 142
Eswaran (B23) 2016; 111
Guglielmetti (B35) 2011; 33
Pineton de Chambrun (B73) 2015; 47
Buono (B10) 2017; 15
Lorenzo-Zuniga (B57) 2014; 20
Yoon (B103) 2015; 57
Black (B6) 2020; 69
Drossman (B19) 2016; 150
Martoni (B61) 2020; 12
Gayathri (B33) 2020; 35
Li (B55) 2020; 11
Frändemark (B31) 2018; 113
Sterne (B93) 2019; 366
Dapoigny (B16) 2012; 18
Ludidi (B58) 2014; 26
Ford (B25) 2018; 48
Ko (B49) 2013; 2013
Simren (B84) 2010; 31
Kim (B46) 2005; 17
Sadrin (B81) 2020; 52
Spiller (B90) 2016; 4
Oh (B70) 2019; 11
Chumpitazi (B14) 2015; 42
Sisson (B86) 2014; 40
Su (B95) 2020; 159
Charbonneau (B12) 2013; 4
Ford (B27); 109
Murakami (B65) 2012; 6
Roberts (B76) 2013; 13
McIntosh (B62) 2017; 66
Thijssen (B97) 2016; 28
Lewis (B54) 2020; 12
Kajander (B42) 2005; 22
Nobaek (B69) 2000; 95
Schumann (B82) 2018; 45
Francis (B30) 1997; 11
Madempudi (B60) 2019; 9
Enck (B22) 2009; 47
Guyonnet (B36) 2007; 26
Wilson (B101) 2020; 115
Sinn (B85) 2008; 53
Rücker (B80) 2020; 62
Wong (B102) 2015; 60
Dionne (B18) 2018; 113
Kim (B48) 2006; 47
Sperber (B89) 2021; 160
Barraza-Ortiz (B4) 2021; 39
Ford (B28); 109
Hod (B37) 2017; 29
Le Morvan de Sequeira (B53) 2021; 10
Su (B96) 2019; 42
Ford (B29) 2020; 396
Gade (B32) 1989; 7
Drouault-Holowacz (B20) 2008; 32
Black (B7) 2021
Kim (B45) 2003; 17
Shin (B83) 2018; 62
Pinto-Sanchez (B74) 2017; 153
Ringel-Kulka (B75) 2011; 45
Kajander (B43) 2008; 27
Andresen (B3) 2020; 5
Goyal (B34) 2021; 36
Farup (B24) 2012; 2012
Irvine (B40) 2016; 150
Catinean (B11) 2019; 11
Staudacher (B92) 2017; 153
Pedersen (B72) 2014; 20
Lyra (B59) 2016; 22
Begtrup (B5) 2013; 48
Hong (B38) 2009; 3
Lacy (B52) 2021; 116
Lacy (B51) 2016; 150
Niedzielin (B66) 2001; 13
Brignardello-Petersen (B9) 2020; 371
Böhn (B8) 2015; 149
Sondergaard (B88) 2011; 46
Whorwell (B99) 2006; 101
Ford (B26) 2017; 376
van Lanen (B98) 2021; 60
Niu (B67) 2020; 75
Rücker (B79) 2021; 63
Kruis (B50) 2012; 27
Agrawal (B2) 2009; 29
Zeng (B105) 2008; 28
Cui (B15) 2012; 5
Mearin (B63) 2004; 99
Williams (B100) 2009; 29
Ki Cha (B44) 2012; 46
Ducrotté (B21) 2012; 18
Niv (B68) 2005; 24
Abbas (B1) 2014; 26
Rogha (B77) 2014; 7
Liang (B56) 2019; 98
Yoon (B104) 2014; 29
Rücker (B78) 2012; 3
Stevenson (B94) 2014; 30
Kim (B47) 2020; 29
Patcharatrakul (B71) 2019; 11
Skrzydło-Radomańska (B87) 2021; 13
Darvishmoghadam (B17) 2019; 45
Hun (B39) 2009; 121
Choi (B13) 2011; 45
Michail (B64) 2011; 3
References_xml – volume: 366
  start-page: l4898
  year: 2019
  ident: B93
  article-title: RoB 2: a Revised Tool for Assessing Risk of Bias in Randomised Trials
  publication-title: BMJ (Clinical research ed.)
  doi: 10.1136/bmj.l4898
– volume: 29
  start-page: 837
  year: 2020
  ident: B47
  article-title: Probiotic Treatment Induced Change of Inflammation Related Metabolites in IBS-D Patients/double-Blind, Randomized, Placebo-Controlled Trial
  publication-title: Food Sci. Biotechnol.
  doi: 10.1007/s10068-019-00717-2
– volume: 33
  start-page: 1123
  year: 2011
  ident: B35
  article-title: Randomised Clinical Trial: Bifidobacterium Bifidum MIMBb75 Significantly Alleviates Irritable Bowel Syndrome and Improves Quality of Life-Aa Double-Blind, Placebo-Controlled Study
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2011.04633.x
– volume: 29
  start-page: 104
  year: 2009
  ident: B2
  article-title: Clinical Trial: The Effects of a Fermented Milk Product Containing Bifidobacterium Lactis DN-173 010 on Abdominal Distension and Gastrointestinal Transit in Irritable Bowel Syndrome with Constipation
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2008.03853.x
– volume: 20
  start-page: 8709
  year: 2014
  ident: B57
  article-title: I.31, a New Combination of Probiotics, Improves Irritable Bowel Syndrome-Related Quality of Life
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v20.i26.8709
– volume: 13
  start-page: 45
  year: 2013
  ident: B76
  article-title: A Randomised Controlled Trial of a Probiotic “Functional Food” in the Management of Irritable Bowel Syndrome
  publication-title: BMC Gastroenterol.
  doi: 10.1186/1471-230X-13-45
– volume: 18
  start-page: 2067
  year: 2012
  ident: B16
  article-title: Efficacy and Safety Profile of LCR35 Complete Freeze-Dried Culture in Irritable Bowel Syndrome: a Randomized, Double-Blind Study
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v18.i17.2067
– volume: 98
  start-page: e16068
  year: 2019
  ident: B56
  article-title: Efficacy of Different Probiotic Protocols in Irritable Bowel Syndrome: A Network Meta-Analysis
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000016068
– volume: 11
  start-page: 2887
  year: 2019
  ident: B70
  article-title: Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
  publication-title: Nutrients
  doi: 10.3390/nu11122887
– volume: 2013
  start-page: 824605
  year: 2013
  ident: B49
  article-title: Effect of Korean Herbal Medicine Combined with a Probiotic Mixture on Diarrhea-Dominant Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo-Controlled Trial
  publication-title: Evid.-Based Complement. Altern. Med.
  doi: 10.1155/2013/824605
– volume: 39
  start-page: 294
  year: 2021
  ident: B4
  article-title: Combination of a Probiotic and an Antispasmodic Increases Quality of Life and Reduces Symptoms in Patients with Irritable Bowel Syndrome: A Pilot Study
  publication-title: Dig. Dis.
  doi: 10.1159/000510950
– volume: 45
  start-page: 24
  year: 2018
  ident: B82
  article-title: Low Fermentable, Oligo-, Di-, Mono-Saccharides and Polyol Diet in the Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
  publication-title: Nutrition
  doi: 10.1016/j.nut.2017.07.004
– volume: 5
  start-page: 238
  year: 2012
  ident: B15
  article-title: Multistrain Probiotic Preparation Significantly Reduces Symptoms of Irritable Bowel Syndrome in a Double-Blind Placebo-Controlled Study
  publication-title: Int. J. Clin. Exp. Med.
– volume: 371
  start-page: m3900
  year: 2020
  ident: B9
  article-title: GRADE Approach to Drawing Conclusions from a Network Meta-Analysis Using a Minimally Contextualised Framework
  publication-title: BMJ
  doi: 10.1136/bmj.m3900
– volume: 45
  start-page: 242
  year: 2019
  ident: B17
  article-title: Assessment of the Effect of Sachet Formulation of almond (Amygdalus Dulcis L.) on Diarrhea Prominent Irritable Bowel Syndrome (IBS-D) Symptoms: A Clinical Trial
  publication-title: Complement. Ther. Med.
  doi: 10.1016/j.ctim.2019.07.001
– volume: 26
  start-page: 705
  year: 2014
  ident: B58
  article-title: Randomized Clinical Trial on the Effect of a Multispecies Probiotic on Visceroperception in Hypersensitive IBS Patients
  publication-title: Neurogastroenterol Motil.
  doi: 10.1111/nmo.12320
– volume: 115
  start-page: 906
  year: 2020
  ident: B101
  article-title: β-Galactooligosaccharide in Conjunction with Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria
  publication-title: Am. J. Gastroenterol.
  doi: 10.14309/ajg.0000000000000641
– volume: 150
  start-page: 1257
  year: 2016
  ident: B19
  article-title: Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2016.03.035
– volume: 53
  start-page: 2714
  year: 2008
  ident: B85
  article-title: Therapeutic Effect of Lactobacillus Acidophilus-SDC 2012, 2013 in Patients with Irritable Bowel Syndrome
  publication-title: Dig. Dis. Sci.
  doi: 10.1007/s10620-007-0196-4
– volume: 15
  start-page: 35
  year: 2017
  ident: B10
  article-title: Health-related Quality of Life, Work Productivity, and Indirect Costs Among Patients with Irritable Bowel Syndrome with Diarrhea
  publication-title: Health Qual. Life Outcomes
  doi: 10.1186/s12955-017-0611-2
– volume: 22
  start-page: 387
  year: 2005
  ident: B42
  article-title: A Probiotic Mixture Alleviates Symptoms in Irritable Bowel Syndrome Patients: a Controlled 6-month Intervention
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2005.02579.x
– volume: 46
  start-page: 220
  year: 2012
  ident: B44
  article-title: The Effect of a Multispecies Probiotic Mixture on the Symptoms and Fecal Microbiota in Diarrhea-Dominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
  publication-title: J. Clin. Gastroenterol.
  doi: 10.1097/MCG.0b013e31823712b1
– volume: 7
  start-page: 23
  year: 1989
  ident: B32
  article-title: Paraghurt for Patients with Irritable Bowel Syndrome. A Controlled Clinical Investigation from General Practice
  publication-title: Scand. J. Prim. Health Care
  doi: 10.3109/02813438909103666
– volume: 47
  start-page: 413
  year: 2006
  ident: B48
  article-title: The Effects of Probiotics on Symptoms of Irritable Bowel Syndrome
  publication-title: Korean J. Gastroenterol.
– volume: 60
  start-page: 3505
  year: 2021
  ident: B98
  article-title: Efficacy of a Low-FODMAP Diet in Adult Irritable Bowel Syndrome: a Systematic Review and Meta-Analysis
  publication-title: Eur. J. Nutr.
  doi: 10.1007/s00394-020-02473-0
– volume: 47
  start-page: 119
  year: 2015
  ident: B73
  article-title: A Randomized Clinical Trial of Saccharomyces cerevisiae versus Placebo in the Irritable Bowel Syndrome
  publication-title: Dig. Liver Dis.
  doi: 10.1016/j.dld.2014.11.007
– volume: 150
  start-page: 1393
  year: 2016
  ident: B51
  article-title: Bowel Disorders
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2016.02.031
– volume: 48
  start-page: 1127
  year: 2013
  ident: B5
  article-title: Long-term Treatment with Probiotics in Primary Care Patients with Irritable Bowel Syndrome-Aa Randomised, Double-Blind, Placebo Controlled Trial
  publication-title: Scand. J. Gastroenterol.
  doi: 10.3109/00365521.2013.825314
– volume: 48
  start-page: 1044
  year: 2018
  ident: B25
  article-title: Systematic Review with Meta-Analysis: the Efficacy of Prebiotics, Probiotics, Synbiotics and Antibiotics in Irritable Bowel Syndrome
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/apt.15001
– volume: 11
  start-page: 395
  year: 1997
  ident: B30
  article-title: The Irritable Bowel Severity Scoring System: a Simple Method of Monitoring Irritable Bowel Syndrome and its Progress
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1046/j.1365-2036.1997.142318000.x
– volume: 17
  start-page: 895
  year: 2003
  ident: B45
  article-title: A Randomized Controlled Trial of a Probiotic, VSL#3, on Gut Transit and Symptoms in Diarrhoea-Predominant Irritable Bowel Syndrome
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1046/j.1365-2036.2003.01543.x
– volume: 2012
  start-page: 214102
  year: 2012
  ident: B24
  article-title: Probiotics, Symptoms, and Gut Microbiota: What Are the Relations? A Randomized Controlled Trial in Subjects with Irritable Bowel Syndrome
  publication-title: Gastroenterol. Res. Pract.
  doi: 10.1155/2012/214102
– volume: 113
  start-page: 1290
  year: 2018
  ident: B18
  article-title: A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-free Diet and a Low FODMAP Diet in Treating Symptoms of Irritable Bowel Syndrome
  publication-title: Am. J. Gastroenterol.
  doi: 10.1038/s41395-018-0195-4
– volume: 11
  start-page: 332
  year: 2020
  ident: B55
  article-title: Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2020.00332
– volume: 159
  start-page: 697
  year: 2020
  ident: B95
  article-title: AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2020.05.059
– volume: 153
  start-page: 936
  year: 2017
  ident: B92
  article-title: A Diet Low in FODMAP Reduces Symptoms in Patients with Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2017.06.010
– volume: 32
  start-page: 147
  year: 2008
  ident: B20
  article-title: A Double Blind Randomized Controlled Trial of a Probiotic Combination in 100 Patients with Irritable Bowel Syndrome
  publication-title: Gastroenterol. Clin. Biol.
  doi: 10.1016/j.gcb.2007.06.001
– volume: 113
  start-page: 1540
  year: 2018
  ident: B31
  article-title: Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem
  publication-title: Am. J. Gastroenterol.
  doi: 10.1038/s41395-018-0262-x
– volume: 75
  start-page: 116
  year: 2020
  ident: B67
  article-title: The Efficacy and Safety of Probiotics in Patients with Irritable Bowel Syndrome: Evidence Based on 35 Randomized Controlled Trials
  publication-title: Int. J. Surg.
  doi: 10.1016/j.ijsu.2020.01.142
– volume: 150
  start-page: 1469
  year: 2016
  ident: B40
  article-title: Design of Treatment Trials for Functional Gastrointestinal Disorders
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2016.02.010
– volume: 101
  start-page: 1581
  year: 2006
  ident: B99
  article-title: Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Women with Irritable Bowel Syndrome
  publication-title: Am. J. Gastroenterol.
  doi: 10.1111/j.1572-0241.2006.00734.x
– volume: 29
  start-page: e13037
  year: 2017
  ident: B37
  article-title: A Double-Blind, Placebo-Controlled Study to Assess the Effect of a Probiotic Mixture on Symptoms and Inflammatory Markers in Women with Diarrhea-Predominant IBS
  publication-title: Neurogastroenterol Motil.
  doi: 10.1111/nmo.13037
– volume: 153
  start-page: 448
  year: 2017
  ident: B74
  article-title: Probiotic Bifidobacterium Longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients with Irritable Bowel Syndrome
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2017.05.003
– volume: 52
  start-page: 534
  year: 2020
  ident: B81
  article-title: A 2-strain Mixture of Lactobacillus Acidophilus in the Treatment of Irritable Bowel Syndrome: A Placebo-Controlled Randomized Clinical Trial
  publication-title: Dig. Liver Dis.
  doi: 10.1016/j.dld.2019.12.009
– volume: 11
  start-page: 1968
  year: 2019
  ident: B11
  article-title: Bacillus Spp. Spores-A Promising Treatment Option for Patients with Irritable Bowel Syndrome
  publication-title: Nutrients
  doi: 10.3390/nu11091968
– volume: 13
  start-page: 756
  year: 2021
  ident: B87
  article-title: The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study
  publication-title: Nutrients
  doi: 10.3390/nu13030756
– volume: 109
  start-page: 1350
  ident: B27
  article-title: Effect of Antidepressants and Psychological Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis
  publication-title: Am. J. Gastroenterol.
  doi: 10.1038/ajg.2014.148
– volume: 121
  start-page: 119
  year: 2009
  ident: B39
  article-title: Bacillus Coagulans Significantly Improved Abdominal Pain and Bloating in Patients with IBS
  publication-title: Postgrad. Med.
  doi: 10.3810/pgm.2009.03.1984
– volume: 9
  start-page: 12210
  year: 2019
  ident: B60
  article-title: Randomized Clinical Trial: the Effect of Probiotic Bacillus Coagulans Unique IS2 vs. Placebo on the Symptoms Management of Irritable Bowel Syndrome in Adults
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-019-48554-x
– volume: 7
  start-page: 156
  year: 2014
  ident: B77
  article-title: The Efficacy of a Synbiotic Containing Bacillus Coagulans in Treatment of Irritable Bowel Syndrome: a Randomized Placebo-Controlled Trial
  publication-title: Gastroenterol. Hepatol. Bed Bench
– volume: 63
  start-page: 447
  year: 2021
  ident: B79
  article-title: Component Network Meta-Analysis Compared to a Matching Method in a Disconnected Network: A Case Study
  publication-title: Biometrical Journal. Biometrische Z.
  doi: 10.1002/bimj.201900339
– volume: 36
  start-page: 2107
  year: 2021
  ident: B34
  article-title: Low Fermentable Oligosaccharide, Disaccharide, Monosaccharide, and Polyol Diet in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Prospective, Randomized Trial
  publication-title: J. Gastroenterol. Hepatol.
  doi: 10.1111/jgh.15410
– volume: 22
  start-page: 10631
  year: 2016
  ident: B59
  article-title: Irritable Bowel Syndrome Symptom Severity Improves Equally with Probiotic and Placebo
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v22.i48.10631
– volume: 396
  start-page: 1675
  year: 2020
  ident: B29
  article-title: Irritable Bowel Syndrome
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)31548-8
– volume: 29
  start-page: 52
  year: 2014
  ident: B104
  article-title: Effect of Multispecies Probiotics on Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
  publication-title: J. Gastroenterol. Hepatol.
  doi: 10.1111/jgh.12322
– volume: 6
  start-page: 16
  year: 2012
  ident: B65
  article-title: The Effect of Lactobacillus Brevis KB290 against Irritable Bowel Syndrome: a Placebo-Controlled Double-Blind Crossover Trial
  publication-title: Biopsychosoc Med.
  doi: 10.1186/1751-0759-6-16
– volume: 42
  start-page: 418
  year: 2015
  ident: B14
  article-title: Randomised Clinical Trial: Gut Microbiome Biomarkers Are Associated with Clinical Response to a Low FODMAP Diet in Children with the Irritable Bowel Syndrome
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/apt.13286
– volume: 27
  start-page: 48
  year: 2008
  ident: B43
  article-title: Clinical Trial: Multispecies Probiotic Supplementation Alleviates the Symptoms of Irritable Bowel Syndrome and Stabilizes Intestinal Microbiota
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2007.03542.x
– volume: 27
  start-page: 467
  year: 2012
  ident: B50
  article-title: A Double-Blind Placebo-Controlled Trial to Study Therapeutic Effects of Probiotic Escherichia coli Nissle 1917 in Subgroups of Patients with Irritable Bowel Syndrome
  publication-title: Int. J. Colorectal Dis.
  doi: 10.1007/s00384-011-1363-9
– volume: 12
  start-page: 363
  year: 2020
  ident: B61
  article-title: Lactobacillus Acidophilus DDS-1 and Bifidobacterium Lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial
  publication-title: Nutrients
  doi: 10.3390/nu12020363
– volume: 18
  start-page: 4012
  year: 2012
  ident: B21
  article-title: Clinical Trial: Lactobacillus Plantarum 299v (DSM 9843) Improves Symptoms of Irritable Bowel Syndrome
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v18.i30.4012
– volume: 20
  start-page: 16215
  year: 2014
  ident: B72
  article-title: Ehealth: Low FODMAP Diet vs Lactobacillus Rhamnosus GG in Irritable Bowel Syndrome
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v20.i43.16215
– volume: 17
  start-page: 687
  year: 2005
  ident: B46
  article-title: A Randomized Controlled Trial of a Probiotic Combination VSL# 3 and Placebo in Irritable Bowel Syndrome with Bloating
  publication-title: Neurogastroenterol Motil.
  doi: 10.1111/j.1365-2982.2005.00695.x
– volume: 26
  start-page: 630
  year: 2014
  ident: B1
  article-title: Cytokine and Clinical Response to Saccharomyces Boulardii Therapy in Diarrhea-Dominant Irritable Bowel Syndrome: A Randomized Trial
  publication-title: Eur. J. Gastroenterol. Hepatol.
  doi: 10.1097/MEG.0000000000000094
– volume: 60
  start-page: 186
  year: 2015
  ident: B102
  article-title: Melatonin Regulation as a Possible Mechanism for Probiotic (VSL#3) in Irritable Bowel Syndrome: a Randomized Double-Blinded Placebo Study
  publication-title: Dig. Dis. Sci.
  doi: 10.1007/s10620-014-3299-8
– volume: 66
  start-page: 1241
  year: 2017
  ident: B62
  article-title: FODMAP Alter Symptoms and the Metabolome of Patients with IBS: a Randomised Controlled Trial
  publication-title: Gut
  doi: 10.1136/gutjnl-2015-311339
– volume: 3
  start-page: 1
  year: 2011
  ident: B64
  article-title: Gut Microbiota Is Not Modified by Randomized, Double-Blind, Placebo-Controlled Trial of VSL#3 in Diarrhea-Predominant Irritable Bowel Syndrome
  publication-title: Probiotics Antimicrob. Proteins
  doi: 10.1007/s12602-010-9059-y
– volume: 13
  start-page: 1143
  year: 2001
  ident: B66
  article-title: A Controlled, Double-Blind, Randomized Study on the Efficacy of Lactobacillus Plantarum 299V in Patients with Irritable Bowel Syndrome
  publication-title: Eur. J. Gastroenterol. Hepatol.
  doi: 10.1097/00042737-200110000-00004
– volume: 4
  start-page: 201
  year: 2013
  ident: B12
  article-title: Fecal Excretion of Bifidobacterium Infantis 35624 and Changes in Fecal Microbiota after Eight Weeks of Oral Supplementation with Encapsulated Probiotic
  publication-title: Gut Microbes
  doi: 10.4161/gmic.24196
– volume: 28
  start-page: 8
  year: 2016
  ident: B97
  article-title: Efficacy of Lactobacillus Casei Shirota for Patients with Irritable Bowel Syndrome
  publication-title: Eur. J. Gastroenterol. Hepatol.
  doi: 10.1097/MEG.0000000000000484
– volume: 11
  start-page: 2856
  year: 2019
  ident: B71
  article-title: Effect of Structural Individual Low-FODMAP Dietary Advice vs. Brief Advice on a Commonly Recommended Diet on IBS Symptoms and Intestinal Gas Production
  publication-title: Nutrients
  doi: 10.3390/nu11122856
– volume: 62
  start-page: 808
  year: 2020
  ident: B80
  article-title: Network Meta-Analysis of Multicomponent Interventions
  publication-title: Biom J.
  doi: 10.1002/bimj.201800167
– volume: 35
  start-page: 139
  year: 2020
  ident: B33
  article-title: Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an Add-On Therapy for Irritable Bowel Syndrome
  publication-title: Int. J. Colorectal Dis.
  doi: 10.1007/s00384-019-03462-4
– volume: 57
  start-page: 129
  year: 2015
  ident: B103
  article-title: Effect of Administering a Multi-Species Probiotic Mixture on the Changes in Fecal Microbiota and Symptoms of Irritable Bowel Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial
  publication-title: J. Clin. Biochem. Nutr.
  doi: 10.3164/jcbn.15-14
– year: 2021
  ident: B7
  article-title: Efficacy of a Low FODMAP Diet in Irritable Bowel Syndrome: Systematic Review and Network Meta-Analysis
  publication-title: Gut
  doi: 10.1136/gutjnl-2021-325214
– volume: 47
  start-page: 209
  year: 2009
  ident: B22
  article-title: Randomized Controlled Treatment Trial of Irritable Bowel Syndrome with a Probiotic E.-coli Preparation (DSM17252) Compared to Placebo
  publication-title: Z. Gastroenterol.
  doi: 10.1055/s-2008-1027702
– volume: 29
  start-page: 97
  year: 2009
  ident: B100
  article-title: Clinical Trial: A Multistrain Probiotic Preparation Significantly Reduces Symptoms of Irritable Bowel Syndrome in a Double-Blind Placebo-Controlled Study
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2008.03848.x
– volume: 3
  start-page: 101
  year: 2009
  ident: B38
  article-title: Effect of Probiotics on Symptoms in Korean Adults with Irritable Bowel Syndrome
  publication-title: Gut Liver
  doi: 10.5009/gnl.2009.3.2.101
– volume: 62
  start-page: 179
  year: 2018
  ident: B83
  article-title: A Double Blind, Placebo-Controlled, Randomized Clinical Trial that Breast Milk Derived-Lactobacillus Gasseri BNR17 Mitigated Diarrhea-Dominant Irritable Bowel Syndrome
  publication-title: J. Clin. Biochem. Nutr.
  doi: 10.3164/jcbn.17-73
– volume: 28
  start-page: 994
  year: 2008
  ident: B105
  article-title: Clinical Trial: Effect of Active Lactic Acid Bacteria on Mucosal Barrier Function in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2008.03818.x
– volume: 142
  start-page: 1510
  year: 2012
  ident: B91
  article-title: Fermentable Carbohydrate Restriction Reduces Luminal Bifidobacteria and Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome
  publication-title: J. Nutr.
  doi: 10.3945/jn.112.159285
– volume: 45
  start-page: 679
  year: 2011
  ident: B13
  article-title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of saccharomyces Boulardii in Irritable Bowel Syndrome: Effect on Quality of Life
  publication-title: J. Clin. Gastroenterol.
  doi: 10.1097/MCG.0b013e318204593e
– volume: 116
  start-page: 17
  year: 2021
  ident: B52
  article-title: ACG Clinical Guideline: Management of Irritable Bowel Syndrome
  publication-title: Am. J. Gastroenterol.
  doi: 10.14309/ajg.0000000000001036
– volume: 24
  start-page: 925
  year: 2005
  ident: B68
  article-title: The Efficacy of Lactobacillus Reuteri ATCC 55730 in the Treatment of Patients with Irritable Bowel Syndrome - A Double Blind, Placebo-Controlled, Randomized Study
  publication-title: Clin. Nutr.
  doi: 10.1016/j.clnu.2005.06.001
– volume: 376
  start-page: 2566
  year: 2017
  ident: B26
  article-title: Irritable Bowel Syndrome
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMra1607547
– volume: 5
  start-page: 658
  year: 2020
  ident: B3
  article-title: Heat-inactivated Bifidobacterium Bifidum MIMBb75 (SYN-HI-001) in the Treatment of Irritable Bowel Syndrome: a Multicentre, Randomised, Double-Blind, Placebo-Controlled Clinical Trial
  publication-title: Lancet Gastroenterol. Hepatol.
  doi: 10.1016/S2468-1253(20)30056-X
– volume: 10
  start-page: 3497
  year: 2021
  ident: B53
  article-title: The Effect of Probiotics on Quality of Life, Depression and Anxiety in Patients with Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
  publication-title: J. Clin. Med.
  doi: 10.3390/jcm10163497
– volume: 3
  start-page: 312
  year: 2012
  ident: B78
  article-title: Network Meta-Analysis, Electrical Networks and Graph Theory
  publication-title: Res. Synth. Methods
  doi: 10.1002/jrsm.1058
– volume: 109
  start-page: 1547
  ident: B28
  article-title: Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-Analysis
  publication-title: Am. J. Gastroenterol.
  doi: 10.1038/ajg.2014.202
– volume: 40
  start-page: 51
  year: 2014
  ident: B86
  article-title: Randomised Clinical Trial: A Liquid Multi-Strain Probiotic vs. Placebo in the Irritable Bowel Syndrome–A 12 Week Double-Blind Study
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/apt.12787
– volume: 111
  start-page: 1824
  year: 2016
  ident: B23
  article-title: A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D
  publication-title: Am. J. Gastroenterol.
  doi: 10.1038/ajg.2016.434
– volume: 160
  start-page: 99
  year: 2021
  ident: B89
  article-title: Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2020.04.014
– volume: 149
  start-page: 1399
  year: 2015
  ident: B8
  article-title: Diet Low in FODMAP Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2015.07.054
– volume: 30
  start-page: 1151
  year: 2014
  ident: B94
  article-title: Randomized Clinical Trial: Effect of Lactobacillus Plantarum 299 V on Symptoms of Irritable Bowel Syndrome
  publication-title: Nutrition
  doi: 10.1016/j.nut.2014.02.010
– volume: 17
  start-page: 466
  year: 2014
  ident: B41
  article-title: Therapeutic Effects, Tolerability and Safety of a Multi-Strain Probiotic in Iranian Adults with Irritable Bowel Syndrome and Bloating
  publication-title: Arch. Iranian Med.
– volume: 99
  start-page: 122
  year: 2004
  ident: B63
  article-title: Splitting Irritable Bowel Syndrome: from Original Rome to Rome II Criteria
  publication-title: Am. J. Gastroenterol.
  doi: 10.1046/j.1572-0241.2003.04024.x
– volume: 26
  start-page: 475
  year: 2007
  ident: B36
  article-title: Effect of a Fermented Milk Containing Bifidobacterium Animalis DN-173 010 on the Health-Related Quality of Life and Symptoms in Irritable Bowel Syndrome in Adults in Primary Care: a Multicentre, Randomized, Double-Blind, Controlled Trial
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2007.03362.x
– volume: 4
  start-page: 353
  year: 2016
  ident: B90
  article-title: Randomized Double Blind Placebo-Controlled Trial of Saccharomyces cerevisiae CNCM I-3856 in Irritable Bowel Syndrome: Improvement in Abdominal Pain and Bloating in Those with Predominant Constipation
  publication-title: United Eur. Gastroenterol. J.
  doi: 10.1177/2050640615602571
– volume: 31
  start-page: 218
  year: 2010
  ident: B84
  article-title: Clinical Trial: the Effects of a Fermented Milk Containing Three Probiotic Bacteria in Patients with Irritable Bowel Syndrome - a Randomized, Double-Blind, Controlled Study
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/j.1365-2036.2009.04183.x
– volume: 12
  start-page: 1159
  year: 2020
  ident: B54
  article-title: Efficacy of Lactobacillus Paracasei Ha-196 and Bifidobacterium Longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study
  publication-title: Nutrients
  doi: 10.3390/nu12041159
– volume: 45
  start-page: 518
  year: 2011
  ident: B75
  article-title: Probiotic Bacteria Lactobacillus Acidophilus NCFM and Bifidobacterium Lactis Bi-07 versus Placebo for the Symptoms of Bloating in Patients with Functional Bowel Disorders: a Double-Blind Study
  publication-title: J. Clin. Gastroenterol.
  doi: 10.1097/MCG.0b013e31820ca4d6
– volume: 46
  start-page: 663
  year: 2011
  ident: B88
  article-title: Effects of Probiotic Fermented Milk on Symptoms and Intestinal flora in Patients with Irritable Bowel Syndrome: a Randomized, Placebo-Controlled Trial
  publication-title: Scand. J. Gastroenterol.
  doi: 10.3109/00365521.2011.565066
– volume: 69
  start-page: 74
  year: 2020
  ident: B6
  article-title: Efficacy of Pharmacological Therapies in Patients with IBS with Diarrhoea or Mixed Stool Pattern: Systematic Review and Network Meta-Analysis
  publication-title: Gut
  doi: 10.1136/gutjnl-2018-318160
– volume: 95
  start-page: 1231
  year: 2000
  ident: B69
  article-title: Alteration of Intestinal Microflora Is Associated with Reduction in Abdominal Bloating and Pain in Patients with Irritable Bowel Syndrome
  publication-title: Am. J. Gastroenterol.
  doi: 10.1111/j.1572-0241.2000.02015.x
– volume: 42
  start-page: 150
  year: 2019
  ident: B96
  article-title: Effects of Low-FODMAP Diet on Irritable Bowel Syndrome Symptoms and Gut Microbiome
  publication-title: Gastroenterol. Nurs.
  doi: 10.1097/SGA.0000000000000428
SSID ssj0000399364
Score 2.3559895
SecondaryResourceType review_article
Snippet Background: Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches...
Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients...
Background: Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 853011
SubjectTerms and polyols
disaccharides
irritable bowel syndrome
low fermentable oligosaccharides
monosaccharides
Pharmacology
probiotics
SummonAdditionalLinks – databaseName: DOAJ Open Access Full Text
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ1LT9wwEICtihOXqu-mtNVUQhwqUryO48S9LdAVrbp0JUDlZo0f0W61yiIIQvz7-hGW3aoql14TW7E8Y89MZvyZkG0jma14afPGNDb3ux_NNS147i0fl4W0Glk47zw-Fkdn_Nt5eb5y1VeoCUt44DRxe5zWKAYGjdUDXkmtJTYlhmybwbpuIgnU27yVYCruwcHuCp7SmD4Kk3vNxRQD_5OxT95C0cFgzRBFXv_fnMw_ayVXjM_oCXnce40wTKN9Sh659hnZmSTs9O0unN6forrahR2Y3AOpb5-TX98XNzD6cTgeTuBw5jrA1sIkAphCB5i18PUy_CTQcwf7ixs3h5MeZPAZhnCyhD1DyiTAz1k3heNUQA5j12GOPdvkBTkbfTk9OMr7OxZyw0XZ5c440VQVZWiFqZjWzvp1qQVSZKgrwwPtx7sVFTItRDg1S2XNGldajoIbWbwkG-2ida8JOMsLatF7ZBi6GSyE8AET1bbERvIiI_RuwpXpAeThHoy58oFIkJGKMlJBRirJKCMfl10uEn3jX433gxSXDQM4Oz7w6qR6dVIPqVNGPtzpgPILLWRPsHWL6yvlPUcfWoX7cTLyKunE8lNF6d02v1dmpFrTlrWxrL9pZ9MI865lKcuKvfkfg98im2E-YomcfEs2ustr9877TJ1-H5fHb0tCFtg
  priority: 102
  providerName: Directory of Open Access Journals
Title Low FODMAP Diet and Probiotics in Irritable Bowel Syndrome: A Systematic Review With Network Meta-analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/35355730
https://www.proquest.com/docview/2645856184
https://pubmed.ncbi.nlm.nih.gov/PMC8959572
https://doaj.org/article/408a61cacdb1479bb9af5a3027ca88f4
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELem8cIL4pvwMRkJ7QEtI3UcO0ZCqGNUA9FRaavYW3T-CC2qktFmGv3v8TlpR1GFeE3iOPH5_Lvz-X5HyCujmJU8s3FpShv71S-JdZLy2CMfV6myGhjmOw9PxcmYf77ILnbIqrxVN4CLra4d1pMaz2eHv34u33uFf4cep8fbN-XlBJDak7FDDz4JZvre8sAksaDBsLP2w8KMYBwIpXoeZ2Plsa2Nc25_ywZSBUL_bVbo34cp_0CnwV1ypzMrab-dB_fIjqvuk_1Ry0u9PKDnN2lWiwO6T0c3jNXLB-THl_qaDr4eD_sjejx1DYXK0lFgaMIGdFrRT3PcRdAzR4_qazejZx3TwVvap2drNmjahhrot2kzoaftCXM6dA3E0JGfPCTjwcfzDydxV4QhNlxkTeyME6WUCQMrjGRaO-sVVwtIgIGWhiMdkLc7JDAtBKbVJipnpcssB8GNSh-R3aqu3BNCneVpYsGbbIDNDKRCeI8q0TaDUvE0IslqwAvTMZRjoYxZ4T0VlFERZFSgjIpWRhF5vW5y2dJz_OvhI5Ti-kFk1g4X6vn3olPUgic5iJ4BY3WPS6W1gjIDjO4ayPOSR-Tlag4UXhMxvAKVq68WhTctve-FBXQi8ridE-uu0szbdX4xjYjcmC0b37J5p5pOAtt3rjKVSfb0P_p9Rm7j74Yjcuo52W3mV-6Ft5kavRf2GvaCPvwGMt0WRg
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low+FODMAP+Diet+and+Probiotics+in+Irritable+Bowel+Syndrome%3A+A+Systematic+Review+With+Network+Meta-analysis&rft.jtitle=Frontiers+in+pharmacology&rft.au=Xie%2C+Chao-Rong&rft.au=Tang%2C+Bin&rft.au=Shi%2C+Yun-Zhou&rft.au=Peng%2C+Wen-Yan&rft.date=2022-03-09&rft.issn=1663-9812&rft.eissn=1663-9812&rft.volume=13&rft.spage=853011&rft_id=info:doi/10.3389%2Ffphar.2022.853011&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon